Clinical trials: Dupilumab
Dermatitis, Atopic
A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis
The purpose of this study is to evaluate the efficacy and safety of bermekimab in participants with moderate to severe atopic dermatitis (AD).
- Trial name
- GENESIS (NCT04791319)
- Testing
- Bermekimab, Dupilumab
- Where
- 42 sites in United States, Canada and 3 more
- Volunteers
- 199 people
- Sponsor
- Janssen Research & Development, LLC
Netherton Syndrome
A Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton Syndrome
To date, there are no effective therapy for the management of Netherton Syndrome (NS) Patients use emollients with a limited efficacy on scaling and no efficacy on skin inflammation and pruritus.
- Trial name
- NS-DUPI (NCT04244006)
- Testing
- Dupilumab Prefilled Syringe
- Where
- 2 sites in France
- Volunteers
- 10 people
- Sponsor
- University Hospital, Toulouse
Atopic Dermatitis
Identifying Atopic Dermatitis Patients at Risk for Developing Conjunctivitis During Dupilumab Treatment
Study on ophthalmological comorbidities and the underlying pathomechanisms of conjunctivitis during dupilumab treatment in atopic dermatitis (AD) patients. Patients participate in the Bioday Registry.
- Trial name
- NCT04276623
- Where
- Netherlands
- Volunteers
- 150 people
- Sponsor
- UMC Utrecht
Asthma
The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma
Primary Objective: To assess the effect of dupilumab on lung inflammation and related changes in airway volumes detectable by functional respiratory imaging Secondary Objective: To evaluate the effect of dupilumab at Week 24 on…
- Trial name
- VESTIGE (NCT04400318)
- Testing
- Dupilumab
- Where
- 65 sites in United States, Bulgaria and 11 more
- Volunteers
- 109 people
- Sponsor
- Sanofi
Asthma
Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma
Primary Objective: To investigate the effects of Dupilumab (SAR231893/REGN668) administered subcutaneously (SC) once weekly (qw) for 12 weeks as compared to placebo on reducing the incidence of asthma exacerbation in participants…
- Trial name
- NCT01312961
- Testing
- Dupilumab, Fluticasone/Salmeterol combination therapy, Fluticasone monotherapy
- Where
- 50 sites in United States
- Volunteers
- 104 people
- Sponsor
- Sanofi
Atopic Dermatitis
An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis
The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetic (PK) parameters of the combination of APG777 + APG990 in adults with moderate-to-severe atopic dermatitis (AD), in comparison to…
- Trial name
- NCT07027527
- Testing
- APG777, APG990, Dupilumab
- Where
- 20 sites in Australia, Canada and 1 more
- Volunteers
- 86 people
- Sponsor
- Apogee Therapeutics, Inc.
Asthma in Children
The Effectiveness and Safety of Dupilumab in Children with Asthma in China: a Real-world Study
Observe the changes of type II inflammation markers, lung function, and symptom scores in asthmatic patients aged 6 to 14 during the use of dupilumab to analyze its efficacy.
- Trial name
- NCT06851403
- Testing
- Dupilumab
- Where
- China
- Volunteers
- 213 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Atopic Dermatitis (AD), Asthma
Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy
The objective is to evaluate the potential effect of exposure to dupilumab in pregnancy compared to the primary comparison group of disease-matched pregnant women who are not exposed to dupilumab, and the secondary comparison…
- Trial name
- NCT04173442
- Testing
- dupilumab
- Where
- United States
- Volunteers
- 581 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Moderate-to-Severe Atopic Dermatitis, Atopic Eczema
Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial
The study is focused on skin of color participants who have moderate-to-severe atopic dermatitis. Atopic dermatitis, also referred to as eczema, is a condition that causes the skin to become itchy, dry, and cracked.
- Trial name
- DISCOVER (NCT05590585)
- Testing
- dupilumab, Topical emollient (moisturizer)
- Where
- 30 sites in United States
- Volunteers
- 124 people
- Sponsor
- Regeneron Pharmaceuticals
Eosinophilic Esophagitis
Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)
The primary objectives of the study by study part are: Part A: To determine the treatment effect of dupilumab compared with placebo in adult and adolescent patients with EoE after 24 weeks of treatment as assessed by histological…
- Trial name
- NCT03633617
- Testing
- Dupilumab
- Where
- 95 sites in United States, Australia and 10 more
- Volunteers
- 321 people
- Sponsor
- Regeneron Pharmaceuticals
Chronic Hand Eczema
Efficacy and Safety of Dupilumab Chronic Hands Eczema Refractory to Highly Potent Topical Corticosteroids
Dupilumab has recently demonstrated high efficacy and good safety profile in the treatment of moderate-to-severe atopic dermatitis.
- Trial name
- DUPECZEMAIN (NCT03861455)
- Testing
- Dupilumab
- Where
- 4 sites in France
- Volunteers
- 94 people
- Sponsor
- University Hospital, Toulouse
Atopic Dermatitis
A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable
The main objective of the trial is to evaluate the efficacy of 2 dose regimens of dupilumab compared to placebo, administered with concomitant topical corticosteroids (TCS), in adult patients with severe AD who are not adequately…
- Trial name
- NCT02755649
- Testing
- Dupilumab
- Where
- 73 sites in Austria, Belgium and 8 more
- Volunteers
- 325 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
A Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in Participants With Moderate to Severe Atopic Dermatitis
This study is expected to include approximately 520 patients with moderate to severe AD, and they will be randomly assigned to the treatment group (IBI3027) and the control group (Dupilumab Injection ) in a 1:1 ratio.
- Trial name
- NCT07754786
- Testing
- Dupilumab Injection, IBI3027
- Where
- China
- Volunteers
- 520 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Atopic Dermatitis
Dupilumab Impact on Skin Resident Memory T Cells
The main objective of the study consists in characterizing the immune cells that are present/persist in the skin and the blood of atopic dermatitis (AD) patients treated with Dupilumab, as well as with potent/very potent topical…
- Trial name
- DupiTrem (NCT03983460)
- Testing
- Dupilumab, Optimized TCS treatment, Biopsies
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Association pour la Recherche Clinique et Immunologique
Chronic Rhinosinusitis With Nasal Polyps
Evaluation of Patient Satisfaction During Treatment With Dupilumab in Severe and Recurrent Nasosinusal Polyposis Despite Appropriate Medical and Surgical Treatment.
Chronic rhinosinusitis with nasal polyps (CRSwNP) or nasal polyposis is a frequent disease leading to a decreased quality of life.
- Trial name
- Dupi-PNS (NCT06017427)
- Testing
- Questionnaires
- Where
- France
- Volunteers
- 32 people
- Sponsor
- IHU Strasbourg
Dermatitis Atopic
Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis
Primary Objective: Evaluate changes in skin barrier function with transepidermal water loss (TEWL) assessed after skin tape stripping (STS) in predefined lesional skin in pediatric participants with moderate to severe atopic…
- Trial name
- PELISTAD (NCT04718870)
- Testing
- Dupilumab SAR231893
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Sanofi
Nasal Polyps, Sinusitis
Dupixent Study for Alternate Administration
Investigators will investigate an alternate Dupilumab administration schedule in patients with recurrent chronic rhinosinusitis with nasal polyposis, who have a history of full endoscopic sinus surgery and are on appropriate…
- Conditions
- Nasal Polyps, Sinusitis, Chronic Disease
- Trial name
- NCT06750471
- Testing
- Dupilumab
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Madigan Army Medical Center
Eosinophilic Esophagitis (EoE)
Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)
The goal of this study is to research Dupilumab, an FDA approved medication in treating patients diagnosed with Eosinophilic esophagitis (EoE). The drug works by controlling allergic inflammation of the esophagus.
- Trial name
- NCT06665971
- Testing
- Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Diego
Atopic Keratoconjunctivitis
Evaluation of Dupilumab in Patients With Atopic Keratoconjunctivitis (AKC)
This is a multi-center, double-masked, randomized, placebo-controlled, parallel-group, efficacy, safety, and tolerability study evaluating the efficacy of Dupilumab in the treatment of signs and symptoms of atopic…
- Trial name
- NCT04296864
- Testing
- Dupilumab
- Where
- 20 sites in United States
- Volunteers
- 42 people
- Sponsor
- Andover Eye Associates
Atopic Dermatitis
Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
This is a randomized, double-blind, double-dummy, active-controlled, multi-center study to assess the efficacy and safety of abrocitinib 200 mg (2 x 100 mg tablets) administered orally QD compared with dupilumab 300 mg…
- Trial name
- NCT04345367
- Testing
- Abrocitinib 200 mg, Dupilumab 300 mg
- Where
- 151 sites in United States, Australia and 13 more
- Volunteers
- 727 people
- Sponsor
- Pfizer